 "babies")
The European Commission has authorised the world's first one-dose drug against a respiratory virus that sickens millions of babies and children globally every year.
In a statement on Friday, drugmakers Sanofi and AstraZeneca said the European Commission had given the green light to nirsevimab, a laboratory-developed antibody designed to protect infants during their first exposure to RSV, or respiratory syncytial virus, a highly contagious common infection that infects nearly all babies by age 2.
At the moment, babies at high risk of the disease can be given monthly shots to protect them during RSV season.
In September, the European Medicines Agency recommended that nirsevimab, sold as Beyfortus, be authorised based on advanced research that showed the drug reduced the chances that babies with RSV needed medical attention and appeared to be safe, compared to infants who got a dummy treatment. The drug is given in a single injection.
We are excited about the opportunity to expand prevention efforts to all infants, said Silke Mader, co-founder of the European Foundation for the Care of Newborn Infants.
Also Read
In the US, RSV is causing an early surge of infections in children's hospitals this year. European health officials are warning there could be a similar spike across the continent.
For most healthy people, RSV is a cold-like nuisance. But the virus can be life-threatening for the very young and the elderly. The virus can infect deep in the lungs and in small babies, it can impede breathing by inflaming their tiny airways.
RSV kills about 100,000 babies annually, mostly in developing countries.
Nirsevimab was developed to give newborns and infants immediate protection against RSV through an antibody to prevent infections in their respiratory systems.
Earlier this week, Pfizer announced preliminary research showing that a new vaccine given to pregnant women could help protect their babies against RSV, after decades of failure to develop an effective shot.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
